Theresa R. Grover
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Theresa R. Grover has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Steven H. Abman
5 shared publicationsThomas A. Parker
4 shared publicationsNeil E. Markham
3 shared publications- Steven H. Abman
Department of Pediatrics, University of Colorado School of Medicine, and Children's Hospital Colorado, Aurora, CO, USA
3 shared publications John P. Kinsella
2 shared publications- John P. Kinsella
Pediatric Heart Lung Center and Department of Pediatrics, University of Colorado School of Medicine, Denver
2 shared publications
Latest Publications
- Open Access
- 1 July 2007
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 293 (1) , L33-L34
The diverse role of inhaled nitric oxide in experimental BPD: reduced fibrin deposition and improved lung growth
Dramatic improvements in neonatal care over the past decade have improved the overall survival of premature infants; however, more than one-third of infants born at less than 1,250 g will ultimately be diagnosed with bronchopulmonary dysplasia (BPD), a complex, multifactorial disease ([21][1]). Preterm birth interrupts normal pulmonary alveolar and vascular development and leads to long-term abnormalities in pulmonary growth and function. Necessary therapies for the management of neonatal respiratory distress syndrome, including mechanical ventilation and oxygen therapy, further contribute to lung injury by releasing toxic free radicals and inflammatory cytokines and disrupt production of critical growth factors in the lung. Although the interactions of numerous growth factors are important for normal pulmonary development, it has been well established that nitric oxide (NO) is among the most critical. Nitric oxide synthase is abundant in epithelial and endothelial cells during fetal development and is responsible for NO oxide production in the lung. Endogenous NO production plays a critical role in both pulmonary vascular and alveolar development, as disruption of NO signaling results in alveolar simplification, impaired pulmonary vascular growth and function, and pulmonary hypertension ([3][2], [9][3]). After birth, NO continues to play an important part in normal lung function by exerting such diverse effects as pulmonary vasodilation ([1][4]), bronchodilation ([7][5]), improved surfactant function ([4][6]), reduced lung inflammation ([6][7], [11][8]), and inhibition of smooth muscle cell proliferation ([8][9]). The use of exogenous, inhaled NO (iNO) has been shown to improve lung growth and function in animal models of hyperoxic lung injury and BPD through a variety of mechanisms ([13][10], [18][11]), and there is keen interest that iNO may be useful to prevent or ameliorate BPD in premature infants. Several recent, large-scale clinical trials have examined the early use of iNO for the prevention of BPD in premature infants, with promising results ([5][12], [12][13], [16][14], [20][15]). Although each of the trials utilized a different strategy for the timing and dosing of iNO, a reduction in BPD and/or death was demonstrated either overall or in subgroups of patients in each of the trials. Schreiber et al. ([16][14]) treated mechanically ventilated infants born at less than 34 wk gestation with iNO (5–10 ppm) during the first week of life and found a reduction in death or survival with BPD in the NO-treated infants. Kinsella et al. ([12][13]) demonstrated a 50% reduction in BPD in infants born at 1,000–1,250 g after treatment with iNO (5 ppm) started within 48 h of birth and continued for a mean of 14 days, although iNO did not reduce BPD for the entire study group. In addition, Ballard et al. ([5][12]) treated infants born weighing less than 1,250 g requiring mechanical ventilation at 7–14 days of life with 5–20 ppm iNO and found improved survival without BPD and shorter duration of oxygen therapy overall. Results of these clinical trials are encouraging and suggest that refinement of dosing, timing, and duration of therapy may lead to a further improvement in certain patient populations at risk for BPD. The authors of each of these studies point out that the exact mechanisms by which iNO improves pulmonary outcomes is unclear but likely is a combination of direct stimulation of alveolar and pulmonary vascular growth, improved airway mechanics, pulmonary vasodilation reducing ventilation/perfusion mismatch, and anti-inflammatory properties of iNO. In this issue of AJP-Lung , ter Horst et al. ([19][16]) present interesting new research suggesting further roles for iNO ([19][16]), which may contribute to improved outcomes after neonatal lung injury. In this study, the authors treated neonatal rats with iNO during hyperoxia after birth and examined its effects on survival, lung growth, and inflammation. Although this study largely confirms past observations, the authors extend previous findings by demonstrating reduced fibrin deposition in the lung, downregulation of inflammatory cytokines (IL-6 and CINC-1), and upregulation of genes involved in alveolarization (FGFR-4 and amphiregulin). As in similar studies, the authors demonstrate modest improvements in lung growth after iNO treatment, including decreased septal thickness and increased alveolar surface area, although iNO-treated lungs exposed to hyperoxia remained markedly simplified when compared with control lungs. In addition, iNO caused an upregulation of FGFR-4 gene expression, which may contribute to improved lung growth, and presents an interesting target for further therapeutic studies. Interestingly, although iNO prolonged survival by 1.5 days in this study, none of the study animals survived the neonatal period after hyperoxia exposure, as iNO did not improve actual survival in this model despite improvements in lung growth and inflammation. Hyperoxia-induced lung injury has been extensively studied in both adult and neonatal animal models and provides an important experimental model for BPD. iNO, when given during periods of hyperoxia in adult rats, improves survival, diminishes inflammation, and protects both the pulmonary endothelium and epithelium from oxidative injury ([10][17], [14][18], [15][19]). Although iNO upregulates other growth factors, most notably vascular endothelial growth factor ([2][20]), and stimulates alveolar and pulmonary vascular growth in neonatal rats exposed to hyperoxia ([13][10], [18][11]), iNO has not previously been shown to improve neonatal survival after lung injury. Given the results of the recent clinical trials in premature infants, it appears that iNO may improve survival without BPD in premature infants, but likely has far-reaching effects beyond direct stimulation of lung growth. Ter Horst et al. ([19][16]) provide evidence of a novel role for iNO in...
- 1 July 2007
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 293 (1) , L33-L34
Open AccessThe diverse role of inhaled nitric oxide in experimental BPD: reduced fibrin deposition and improved lung growth
Dramatic improvements in neonatal care over the past decade have improved the overall survival of premature infants; however, more than one-third of infants born at less than 1,250 g will ultimately be diagnosed with bronchopulmonary dysplasia (BPD), a complex, multifactorial disease ([21][1]). Preterm birth interrupts normal pulmonary alveolar and vascular development and leads to long-term abnormalities in pulmonary growth and function. Necessary therapies for the management of neonatal respiratory distress syndrome, including mechanical ventilation and oxygen therapy, further contribute to lung injury by releasing toxic free radicals and inflammatory cytokines and disrupt production of critical growth factors in the lung. Although the interactions of numerous growth factors are important for normal pulmonary development, it has been well established that nitric oxide (NO) is among the most critical. Nitric oxide synthase is abundant in epithelial and endothelial cells during fetal development and is responsible for NO oxide production in the lung. Endogenous NO production plays a critical role in both pulmonary vascular and alveolar development, as disruption of NO signaling results in alveolar simplification, impaired pulmonary vascular growth and function, and pulmonary hypertension ([3][2], [9][3]). After birth, NO continues to play an important part in normal lung function by exerting such diverse effects as pulmonary vasodilation ([1][4]), bronchodilation ([7][5]), improved surfactant function ([4][6]), reduced lung inflammation ([6][7], [11][8]), and inhibition of smooth muscle cell proliferation ([8][9]). The use of exogenous, inhaled NO (iNO) has been shown to improve lung growth and function in animal models of hyperoxic lung injury and BPD through a variety of mechanisms ([13][10], [18][11]), and there is keen interest that iNO may be useful to prevent or ameliorate BPD in premature infants. Several recent, large-scale clinical trials have examined the early use of iNO for the prevention of BPD in premature infants, with promising results ([5][12], [12][13], [16][14], [20][15]). Although each of the trials utilized a different strategy for the timing and dosing of iNO, a reduction in BPD and/or death was demonstrated either overall or in subgroups of patients in each of the trials. Schreiber et al. ([16][14]) treated mechanically ventilated infants born at less than 34 wk gestation with iNO (5–10 ppm) during the first week of life and found a reduction in death or survival with BPD in the NO-treated infants. Kinsella et al. ([12][13]) demonstrated a 50% reduction in BPD in infants born at 1,000–1,250 g after treatment with iNO (5 ppm) started within 48 h of birth and continued for a mean of 14 days, although iNO did not reduce BPD for the entire study group. In addition, Ballard et al. ([5][12]) treated infants born weighing less than 1,250 g requiring mechanical ventilation at 7–14 days of life with 5–20 ppm iNO and found improved survival without BPD and shorter duration of oxygen therapy overall. Results of these clinical trials are encouraging and suggest that refinement of dosing, timing, and duration of therapy may lead to a further improvement in certain patient populations at risk for BPD. The authors of each of these studies point out that the exact mechanisms by which iNO improves pulmonary outcomes is unclear but likely is a combination of direct stimulation of alveolar and pulmonary vascular growth, improved airway mechanics, pulmonary vasodilation reducing ventilation/perfusion mismatch, and anti-inflammatory properties of iNO. In this issue of AJP-Lung , ter Horst et al. ([19][16]) present interesting new research suggesting further roles for iNO ([19][16]), which may contribute to improved outcomes after neonatal lung injury. In this study, the authors treated neonatal rats with iNO during hyperoxia after birth and examined its effects on survival, lung growth, and inflammation. Although this study largely confirms past observations, the authors extend previous findings by demonstrating reduced fibrin deposition in the lung, downregulation of inflammatory cytokines (IL-6 and CINC-1), and upregulation of genes involved in alveolarization (FGFR-4 and amphiregulin). As in similar studies, the authors demonstrate modest improvements in lung growth after iNO treatment, including decreased septal thickness and increased alveolar surface area, although iNO-treated lungs exposed to hyperoxia remained markedly simplified when compared with control lungs. In addition, iNO caused an upregulation of FGFR-4 gene expression, which may contribute to improved lung growth, and presents an interesting target for further therapeutic studies. Interestingly, although iNO prolonged survival by 1.5 days in this study, none of the study animals survived the neonatal period after hyperoxia exposure, as iNO did not improve actual survival in this model despite improvements in lung growth and inflammation. Hyperoxia-induced lung injury has been extensively studied in both adult and neonatal animal models and provides an important experimental model for BPD. iNO, when given during periods of hyperoxia in adult rats, improves survival, diminishes inflammation, and protects both the pulmonary endothelium and epithelium from oxidative injury ([10][17], [14][18], [15][19]). Although iNO upregulates other growth factors, most notably vascular endothelial growth factor ([2][20]), and stimulates alveolar and pulmonary vascular growth in neonatal rats exposed to hyperoxia ([13][10], [18][11]), iNO has not previously been shown to improve neonatal survival after lung injury. Given the results of the recent clinical trials in premature infants, it appears that iNO may improve survival without BPD in premature infants, but likely has far-reaching effects beyond direct stimulation of lung growth. Ter Horst et al. ([19][16]) provide evidence of a novel role for iNO in...
- Open Access
- 1 June 2007
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 292 (6) , L1345-L1351
Hypoxia-inducible factors HIF-1α and HIF-2α are decreased in an experimental model of severe respiratory distress syndrome in preterm lambs
Respiratory distress syndrome (RDS) secondary to preterm birth and surfactant deficiency is characterized by severe hypoxemia, lung injury, and impaired production of nitric oxide (NO) and vascular endothelial growth factor (VEGF). Since hypoxia-inducible factors (HIFs) mediate the effects of both NO and VEGF in part through regulation by prolyl-hydroxylase-containing domains (PHDs) in the presence of oxygen, we hypothesized that HIF-1α and -2α in the lung are decreased following severe RDS in preterm neonatal lambs. To test this hypothesis, fetal lambs were delivered at preterm gestation (115-day gestation, term = 145 days; n = 4) and mechanically ventilated for 4 h. Lambs developed respiratory failure characterized by severe hypoxemia despite treatment with mechanical ventilation with high inspired oxygen concentrations. Lung samples were compared with nonventilated control animals at preterm (115-day gestation; n = 3) and term gestation (142-day gestation; n = 3). We found that HIF-1α protein expression decreased ( P < 0.05) and PHD-2 expression increased ( P < 0.005) at birth in normal term animals before air breathing. Compared with age-matched controls, HIF-1α protein and HIF-2α protein expression decreased by 80% and 55%, respectively ( P < 0.005 for each) in preterm lambs with RDS. Furthermore, VEGF mRNA was decreased by 40%, and PHD-2 protein expression doubled in RDS lambs. We conclude that pulmonary expression of HIF-1α, HIF-2α, and the downstream target of their regulation, VEGF mRNA, is impaired following RDS in neonatal lambs. We speculate that early disruption of HIF and VEGF expression after preterm birth and RDS may contribute to long-term abnormalities in lung growth, leading to bronchopulmonary dysplasia.
- 1 June 2007
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 292 (6) , L1345-L1351
Open AccessHypoxia-inducible factors HIF-1α and HIF-2α are decreased in an experimental model of severe respiratory distress syndrome in preterm lambs
Respiratory distress syndrome (RDS) secondary to preterm birth and surfactant deficiency is characterized by severe hypoxemia, lung injury, and impaired production of nitric oxide (NO) and vascular endothelial growth factor (VEGF). Since hypoxia-inducible factors (HIFs) mediate the effects of both NO and VEGF in part through regulation by prolyl-hydroxylase-containing domains (PHDs) in the presence of oxygen, we hypothesized that HIF-1α and -2α in the lung are decreased following severe RDS in preterm neonatal lambs. To test this hypothesis, fetal lambs were delivered at preterm gestation (115-day gestation, term = 145 days; n = 4) and mechanically ventilated for 4 h. Lambs developed respiratory failure characterized by severe hypoxemia despite treatment with mechanical ventilation with high inspired oxygen concentrations. Lung samples were compared with nonventilated control animals at preterm (115-day gestation; n = 3) and term gestation (142-day gestation; n = 3). We found that HIF-1α protein expression decreased ( P < 0.05) and PHD-2 expression increased ( P < 0.005) at birth in normal term animals before air breathing. Compared with age-matched controls, HIF-1α protein and HIF-2α protein expression decreased by 80% and 55%, respectively ( P < 0.005 for each) in preterm lambs with RDS. Furthermore, VEGF mRNA was decreased by 40%, and PHD-2 protein expression doubled in RDS lambs. We conclude that pulmonary expression of HIF-1α, HIF-2α, and the downstream target of their regulation, VEGF mRNA, is impaired following RDS in neonatal lambs. We speculate that early disruption of HIF and VEGF expression after preterm birth and RDS may contribute to long-term abnormalities in lung growth, leading to bronchopulmonary dysplasia.
- 1 August 2005
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 289 (2) , L315-L321
rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep
We have previously shown that lung VEGF expression is decreased in a fetal lamb model of PPHN and that VEGF165 inhibition causes severe pulmonary hypertension in fetal lambs. Therefore, we hypothesized that treatment with rhVEGF165 would preserve endothelium-dependent vasodilation and reduce the severity of pulmonary vascular remodeling in an experimental model of PPHN. We studied the effects of daily intrapulmonary infusions of rhVEGF after partial ligation of the ductus arteriosus (DA). We performed surgery in 24 late-gestation fetal lambs and placed catheters in the main pulmonary artery, left atrium, and aorta for pressure measurements and in the left pulmonary artery for drug infusions. A pressure transducer was placed around the LPA to measure blood flow to the left lung (Qp), and the DA was surgically constricted to induce pulmonary hypertension. rhVEGF165 or vehicle was infused for 7 or 14 days. ACh or 8-BrcGMP was infused on days 2 and 13 to assess endothelium-dependent and -independent vasodilation, respectively. ACh-induced vasodilation was reduced in PPHN lambs after 14 days (change in Qp from baseline, 106% vs. 11%). In contrast, the response to ACh was preserved in lambs treated with rhVEGF (change in Qp, 94% vs. 90%). Pulmonary vasodilation to 8-BrcGMP was not altered in PPHN lambs or enhanced by VEGF treatment. rhVEGF treatment increased expression of lung eNOS protein and decreased pulmonary artery wall thickness by 34% vs. PPHN lambs. We conclude that VEGF165 preserves endothelium-dependent vasodilation, upregulates eNOS expression, and reduces the severity of pulmonary vascular remodeling in experimental PPHN.
- 1 August 2005
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 289 (2) , L315-L321
rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep
We have previously shown that lung VEGF expression is decreased in a fetal lamb model of PPHN and that VEGF165 inhibition causes severe pulmonary hypertension in fetal lambs. Therefore, we hypothesized that treatment with rhVEGF165 would preserve endothelium-dependent vasodilation and reduce the severity of pulmonary vascular remodeling in an experimental model of PPHN. We studied the effects of daily intrapulmonary infusions of rhVEGF after partial ligation of the ductus arteriosus (DA). We performed surgery in 24 late-gestation fetal lambs and placed catheters in the main pulmonary artery, left atrium, and aorta for pressure measurements and in the left pulmonary artery for drug infusions. A pressure transducer was placed around the LPA to measure blood flow to the left lung (Qp), and the DA was surgically constricted to induce pulmonary hypertension. rhVEGF165 or vehicle was infused for 7 or 14 days. ACh or 8-BrcGMP was infused on days 2 and 13 to assess endothelium-dependent and -independent vasodilation, respectively. ACh-induced vasodilation was reduced in PPHN lambs after 14 days (change in Qp from baseline, 106% vs. 11%). In contrast, the response to ACh was preserved in lambs treated with rhVEGF (change in Qp, 94% vs. 90%). Pulmonary vasodilation to 8-BrcGMP was not altered in PPHN lambs or enhanced by VEGF treatment. rhVEGF treatment increased expression of lung eNOS protein and decreased pulmonary artery wall thickness by 34% vs. PPHN lambs. We conclude that VEGF165 preserves endothelium-dependent vasodilation, upregulates eNOS expression, and reduces the severity of pulmonary vascular remodeling in experimental PPHN.
- 1 April 2005
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 288 (4) , L648-L654
Pulmonary hypertension impairs alveolarization and reduces lung growth in the ovine fetus
Persistent pulmonary hypertension of the newborn (PPHN) is a clinical disorder characterized by abnormal vascular structure, growth, and reactivity. Disruption of vascular growth during early postnatal lung development impairs alveolarization, and newborns with lung hypoplasia often have severe pulmonary hypertension. To determine whether pulmonary hypertension can directly impair vascular growth and alveolarization in the fetus, we studied the effects of chronic intrauterine pulmonary hypertension on lung growth in fetal lambs. We performed surgery, which included partial constriction of the ductus arteriosus (DA) to induce pulmonary hypertension (PH, n = 14) or sham surgery (controls, n = 13) in fetal lambs at 112–125 days (term = 147 days). Tissues were harvested near term for measurement of right ventricular hypertrophy (RVH), radial alveolar counts (RAC), mean linear intercepts (MLI), wall thickness, and vessel density of small pulmonary arteries. Chronic DA constriction caused RVH ( P < 0.0001), increased wall thickness of small pulmonary arteries ( P < 0.002), and reduced small pulmonary artery density ( P < 0.005). PH also reduced alveolarization, causing a 27% reduction in RAC and 20% increase in MLI. Furthermore, prolonged DA constriction (21 days) not only decreased RAC and increased MLI by 30% but also caused a 25% reduction of lung-body weight ratio. We conclude that chronic PH reduces pulmonary arterial growth, decreases alveolar complexity, and impairs lung growth. We speculate that chronic hypertension impairs vascular growth, which disrupts critical signaling pathways regulating lung vascular and alveolar development, thereby interfering with alveolarization and ultimately resulting in lung hypoplasia.
- 1 April 2005
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 288 (4) , L648-L654
Pulmonary hypertension impairs alveolarization and reduces lung growth in the ovine fetus
Persistent pulmonary hypertension of the newborn (PPHN) is a clinical disorder characterized by abnormal vascular structure, growth, and reactivity. Disruption of vascular growth during early postnatal lung development impairs alveolarization, and newborns with lung hypoplasia often have severe pulmonary hypertension. To determine whether pulmonary hypertension can directly impair vascular growth and alveolarization in the fetus, we studied the effects of chronic intrauterine pulmonary hypertension on lung growth in fetal lambs. We performed surgery, which included partial constriction of the ductus arteriosus (DA) to induce pulmonary hypertension (PH, n = 14) or sham surgery (controls, n = 13) in fetal lambs at 112–125 days (term = 147 days). Tissues were harvested near term for measurement of right ventricular hypertrophy (RVH), radial alveolar counts (RAC), mean linear intercepts (MLI), wall thickness, and vessel density of small pulmonary arteries. Chronic DA constriction caused RVH ( P < 0.0001), increased wall thickness of small pulmonary arteries ( P < 0.002), and reduced small pulmonary artery density ( P < 0.005). PH also reduced alveolarization, causing a 27% reduction in RAC and 20% increase in MLI. Furthermore, prolonged DA constriction (21 days) not only decreased RAC and increased MLI by 30% but also caused a 25% reduction of lung-body weight ratio. We conclude that chronic PH reduces pulmonary arterial growth, decreases alveolar complexity, and impairs lung growth. We speculate that chronic hypertension impairs vascular growth, which disrupts critical signaling pathways regulating lung vascular and alveolar development, thereby interfering with alveolarization and ultimately resulting in lung hypoplasia.
- 1 March 2003
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 284 (3) , L508-L517
Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus
Although vascular endothelial growth factor (VEGF) plays a vital role in lung vascular growth in the embryo, its role in maintaining endothelial function and modulating vascular structure during late fetal life has not been studied. We hypothesized that impaired lung VEGF signaling causes pulmonary hypertension, endothelial dysfunction, and structural remodeling before birth. To determine whether lung VEGF expression is decreased in an experimental model of persistent pulmonary hypertension of the newborn (PPHN), we measured lung VEGF and VEGF receptor protein content from fetal lambs 7–10 days after ductus arteriosus ligation (132–140 days gestation; term = 147 days). In contrast with the surge in lung VEGF expression during late gestation in controls, chronic intrauterine pulmonary hypertension reduced lung VEGF expression by 78%. To determine whether VEGF inhibition during late gestation causes pulmonary hypertension, we treated fetal lambs with EYE001, an aptamer that specifically inhibits VEGF165. Compared with vehicle controls, EYE001 treatment elevated pulmonary artery pressure and pulmonary vascular resistance by 22 and 50%, respectively, caused right ventricular hypertrophy, and increased wall thickness of small pulmonary arteries. EYE001 treatment reduced lung endothelial nitric oxide synthase protein content by 50% and preferentially impaired the pulmonary vasodilator response to ACh, an endothelium-dependent agent. We conclude that chronic intrauterine pulmonary hypertension markedly decreases lung VEGF expression and that selective inhibition of VEGF165 mimics the structural and physiological changes of experimental PPHN. We speculate that hypertension downregulates VEGF expression in the developing lung and that impaired VEGF signaling may contribute to the pathogenesis of PPHN.
- 1 March 2003
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 284 (3) , L508-L517
Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus
Although vascular endothelial growth factor (VEGF) plays a vital role in lung vascular growth in the embryo, its role in maintaining endothelial function and modulating vascular structure during late fetal life has not been studied. We hypothesized that impaired lung VEGF signaling causes pulmonary hypertension, endothelial dysfunction, and structural remodeling before birth. To determine whether lung VEGF expression is decreased in an experimental model of persistent pulmonary hypertension of the newborn (PPHN), we measured lung VEGF and VEGF receptor protein content from fetal lambs 7–10 days after ductus arteriosus ligation (132–140 days gestation; term = 147 days). In contrast with the surge in lung VEGF expression during late gestation in controls, chronic intrauterine pulmonary hypertension reduced lung VEGF expression by 78%. To determine whether VEGF inhibition during late gestation causes pulmonary hypertension, we treated fetal lambs with EYE001, an aptamer that specifically inhibits VEGF165. Compared with vehicle controls, EYE001 treatment elevated pulmonary artery pressure and pulmonary vascular resistance by 22 and 50%, respectively, caused right ventricular hypertrophy, and increased wall thickness of small pulmonary arteries. EYE001 treatment reduced lung endothelial nitric oxide synthase protein content by 50% and preferentially impaired the pulmonary vasodilator response to ACh, an endothelium-dependent agent. We conclude that chronic intrauterine pulmonary hypertension markedly decreases lung VEGF expression and that selective inhibition of VEGF165 mimics the structural and physiological changes of experimental PPHN. We speculate that hypertension downregulates VEGF expression in the developing lung and that impaired VEGF signaling may contribute to the pathogenesis of PPHN.
- 1 April 1999
- Published by Springer Nature in Pediatric Research
- Vol. 45 (4, Part 2 ) , 69A
Aminoguanidine, a Selective Type II (Inducible) Nitric Oxide Synthase Antagonist, Attenuates Vasodilation to Birth-Related Stimuli in the Ovine Lung
- 1 April 1999
- Published by Springer Nature in Pediatric Research
- Vol. 45 (4, Part 2 ) , 69A
Aminoguanidine, a Selective Type II (Inducible) Nitric Oxide Synthase Antagonist, Attenuates Vasodilation to Birth-Related Stimuli in the Ovine Lung
- 1 April 1999
- Published by Springer Nature in Pediatric Research
- Vol. 45 (4, Part 2 ) , 66A
Repetitive Prenatal Glucocorticoids Increase Endothelial Nitric Oxide Synthase Expression in Ovine Fetuses Delivered at Term
- 1 April 1999
- Published by Springer Nature in Pediatric Research
- Vol. 45 (4, Part 2 ) , 66A
Repetitive Prenatal Glucocorticoids Increase Endothelial Nitric Oxide Synthase Expression in Ovine Fetuses Delivered at Term
- 1 April 1999
- Published by Springer Nature in Pediatric Research
- Vol. 45 (4, Part 2 ) , 303A
Pulmonary Vascular Effects of Inhaled Carbon Monoxide on the Ovine Transitional Circulation
- 1 April 1999
- Published by Springer Nature in Pediatric Research
- Vol. 45 (4, Part 2 ) , 303A
Pulmonary Vascular Effects of Inhaled Carbon Monoxide on the Ovine Transitional Circulation